Flag of the European Union EU Clinical Trials Register Help

Clinical trials for octreotide acetate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    34 result(s) found for: octreotide acetate. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2021-000849-40 Sponsor Protocol Number: HS-19-657 Start Date*: 2021-10-25
    Sponsor Name:Camurus AB
    Full Title: A randomized, multi-center, open-label, active-controlled Phase 3 trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) versus octreotide LAR or lanreotide ATG in patie...
    Medical condition: gastroenteropancreatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) HU (Trial now transitioned) DE (Ongoing) NL (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001200-38 Sponsor Protocol Number: OTIS2019_001 Start Date*: 2020-11-17
    Sponsor Name:Karolinska Universitetssjukhuset
    Full Title: Octreotide treatment to improve nutritional recovery after surgery for patients with esophageal or gastric cancer, a prospective randomized open label phase II study - OTIS
    Medical condition: Undesired weight loss after operation for esophageal or gastric cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10027415 Metabolic abnormality management PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002854-11 Sponsor Protocol Number: OOC-ACM-302 Start Date*: 2016-04-18
    Sponsor Name:Chiasma, Inc.
    Full Title: A PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, MULTICENTER STUDY TO EVALUATE MAINTENANCE OF RESPONSE, SAFETY AND PATIENT REPORTED OUTCOMES IN ACROMEGALY PATIENTS TREATED WITH OCTREOTIDE CAPS...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) RO (Completed) LT (Completed) DE (Completed) NL (Prematurely Ended) ES (Completed) AT (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003327-23 Sponsor Protocol Number: IP107-001 Start Date*: 2008-10-29
    Sponsor Name:Endo Pharmaceuticals Solutions Inc
    Full Title: PHASE III, OPEN-LABEL, MULTICENTER INTERNATIONAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN OCTREOTIDE IMPLANT VERSUS SANDOSTATIN LAR® DEPOT IN PATIENTS WITH ACROMEGALY
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed) DE (Completed) ES (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-004162-41 Sponsor Protocol Number: C2L-OCT-01 PR-303 Start Date*: 2007-10-25
    Sponsor Name:Mallinckrodt Inc.
    Full Title: SAFETY AND BIOLOGICAL ACTIVITY OF A NEW PROLONGED RELEASE FORMULATION OF OCTREOTIDE ACETATE, C2L-OCT-01 PR, ADMINISTERED INTRA MUSCULARLY EVERY 6 WEEKS IN ACROMEGALIC PATIENTS
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005049-11 Sponsor Protocol Number: AAA-III-01 Start Date*: 2012-04-25
    Sponsor Name:Advanced Accelerator Applications
    Full Title: A multi-centre, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperabl...
    Medical condition: Patients with inoperable, progressive, OctreoScan® positive, well-differentiated neuroendocrine tumours of the small bowel (midgut carcinoid tumours), who are treated with 20 mg or 30 mg Octreotide...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062392 Carcinoid tumor of the small bowel LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) IT (Completed) BE (Completed) PT (Completed) FR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000737-31 Sponsor Protocol Number: OOC-ACM-303 Start Date*: 2017-10-27
    Sponsor Name:Chiasma, Inc.
    Full Title: A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of octreotide capsules in patients who previously tolerated and demonstrated biochemical c...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) NL (Completed) SE (Completed) DK (Completed) PL (Completed) IT (Completed) BG (Completed) LV (Completed) SI (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2013-003183-31 Sponsor Protocol Number: DSC/13/2984/05 Start Date*: 2014-02-25
    Sponsor Name:ITALFARMACO S.p.A.
    Full Title: A Randomized, Multicenter, Phase II study to Investigate Efficacy and Safety of ITF2984 in Acromegalic patients.
    Medical condition: Acromegaly
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed) NL (Completed) HU (Completed) ES (Completed) RO (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-003784-23 Sponsor Protocol Number: ML3244 Start Date*: 2005-11-18
    Sponsor Name:University Hospital Gasthuisberg
    Full Title: EEN FASE II STUDIE DIE DE WERKZAAMHEID NAGAAT VAN SANDOSTATINE LAR® 20 MG EN 30 MG IN DE PREVENTIE VAN CHEMOTHERAPIE EN RADIOTHERAPIE GEÏNDUCEERDE DIARREE BIJ PATIËNTEN DIE PREOPERATIEF BEHANDELD W...
    Medical condition: Locally advanced rectal cancer patients receiving preoperative chemoradiotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004328-39 Sponsor Protocol Number: INFUTER Start Date*: 2020-04-13
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica_FCRB
    Full Title: Hemodynamic profile of terlipressin and octreotide in patients with cirrhosis and portal hypertension. A randomised, single blinded clinical trial.
    Medical condition: The proposed study aims to investigate the hemodynamic effects of terlipressin and the time profile of these effects in patients with cirrhosis and portal hypertension when given as continuous infu...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004320-21 Sponsor Protocol Number: C2L-OCT-01 PR-302 Start Date*: 2007-10-29
    Sponsor Name:Ambrilia Biopharma Inc.
    Full Title: OPEN LABEL EXTENSION STUDY EVALUATING THE SAFETY AND BIOLOGICAL ACTIVITY OF A NEW PROLONGED RELEASE FORMULATION OF OCTREOTIDE ACETATE, C2L-OCT-01 PR, ADMINISTERED INTRA MUSCULARLY EVERY 6 WEEKS IN ...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000533-12 Sponsor Protocol Number: HS-12-455 Start Date*: 2014-07-02
    Sponsor Name:Camurus AB
    Full Title: A Phase II, Open-label, Multicentre, Randomised Study of the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of CAM2029 in Two Patient Groups with Acromegaly and Neuroendocrine Tumours (NE...
    Medical condition: acromegaly; neuroendocrine tumours
    Disease: Version SOC Term Classification Code Term Level
    17.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005855-14 Sponsor Protocol Number: C2L-OCT-01 PR-301 Start Date*: 2007-02-22
    Sponsor Name:Ambrilia Biopharma Inc.
    Full Title: OPEN LABEL, RANDOMIZED STUDY COMPARING THE BIOLOGICAL EFFICACY AND SAFETY OF A NEW PROLONGED RELEASE FORMULATION OF OCTREOTIDE ACETATE, C2L-OCT-01 PR, 30 MG ADMINISTERED INTRA MUSCULARLY EVERY 42 D...
    Medical condition: Acromegaly
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000256-28 Sponsor Protocol Number: LAP117314 Start Date*: 2014-08-21
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomised, Multicentre, Open Label, Phase II study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib with Capecitabine for t...
    Medical condition: Diarrhoea associated with treatment with lapatinib and capecitabine for metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) GB (Completed) IT (Completed) GR (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2022-000507-12 Sponsor Protocol Number: RYZ101-301 Start Date*: 2023-06-12
    Sponsor Name:RayzeBio, Inc.
    Full Title: Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing...
    Medical condition: gastro-enteropancreatic neuroendocrine tumors (GEP-NETs)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000114-10 Sponsor Protocol Number: LF-PB/11/04 Start Date*: 2012-10-09
    Sponsor Name:CHEMI S.P.A.
    Full Title: A Randomized, Double-Blind, Double Dummy, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of LF-PB 10 mg, 20 mg, and 30 mg to Treat Lymphorrhea Post Axillary Dissection in Breast ...
    Medical condition: Patient undergoing breast surgery with axillary lymph node dissection.
    Disease: Version SOC Term Classification Code Term Level
    15.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001292-51 Sponsor Protocol Number: CH-ACM-01-FU Start Date*: 2015-06-30
    Sponsor Name:Chiasma, Inc.
    Full Title: Follow-Up Study in Patients with Acromegaly Previously Participating in Chiasma Study CH-ACM-01
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    17.1 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) SI (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001562-15 Sponsor Protocol Number: CAAA601A22301 Start Date*: 2019-11-15
    Sponsor Name:Advanced Accelerator Applications SA
    Full Title: This is a multicenter, stratified, randomized, open-label comparator-controlled, Phase III study in patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs, d...
    Medical condition: Patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Ongoing) NL (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-005642-37 Sponsor Protocol Number: sandopouch-01 Start Date*: 2007-04-10
    Sponsor Name:University of Leuven, Division of Gastroenterology
    Full Title: Sandostatin® in the treatment of diarrhea in patients with ileal pouch anal anastomosis.
    Medical condition: IPAA Pouchitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004707-12 Sponsor Protocol Number: CRAD001C2X01B Start Date*: 2013-05-16
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multi-center everolimus roll-over protocol for patients who have completed a previous Novartis-sponsored everolimus study and are judged by the investigator to benefit from continued...
    Medical condition: Disease corresponding to the Novartis-sponsored study the patient will be transitioning from
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Prematurely Ended) IT (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 12 07:41:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA